Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rickenbacher

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
International Journal of Cardiology|March 5, 2013
Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney diseaseMaria Wanitschek, Matthias Pfisterer, Anders Hvelplund, et al.
JAMA|March 8, 2003
Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trialMatthias Pfisterer, Peter Buser, Stefan Osswald, et al.
Clinical Chemistry|March 4, 2016
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HFSandra Sanders-van Wijk, Serge Masson, Valentina Milani, et al.
Circulation. Heart Failure|December 20, 2013
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHFSandra Sanders-van Wijk, Micha T Maeder, Fabian Nietlispach, et al.
Journal of Cardiac Failure|February 25, 2017
N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHFNasser Davarzani, Sandra Sanders-van Wijk, Joël Karel, et al.
JACC. Heart Failure|March 14, 2014
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Sandra Sanders-van Wijk, Antoinette D I van Asselt, Hans Rickli, et al.
European Heart Journal|November 10, 2011
End-of-life preferences of elderly patients with chronic heart failureHans-Peter Brunner-La Rocca, Peter Rickenbacher, Stefano Muzzarelli, et al.
The American Journal of Medicine|May 4, 2019
Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF TrialJustas Simonavičius, Sandra Sanders van-Wijk, Peter Rickenbacher, et al.
JACC. Cardiovascular Interventions|August 20, 2021
Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 TrialJochen Wöhrle, Bruno Scheller, Julia Seeger, et al.
Circulation. Cardiovascular Interventions|January 10, 2022
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2Norman Mangner, Ahmed Farah, Marc-Alexander Ohlow, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
International Journal of Cardiology|March 5, 2013
Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney diseaseMaria Wanitschek, Matthias Pfisterer, Anders Hvelplund, et al.
JAMA|March 8, 2003
Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trialMatthias Pfisterer, Peter Buser, Stefan Osswald, et al.
Clinical Chemistry|March 4, 2016
Interaction of Galectin-3 Concentrations with the Treatment Effects of β-Blockers and RAS Blockade in Patients with Systolic Heart Failure: A Derivation-Validation Study from TIME-CHF and GISSI-HFSandra Sanders-van Wijk, Serge Masson, Valentina Milani, et al.
Circulation. Heart Failure|December 20, 2013
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHFSandra Sanders-van Wijk, Micha T Maeder, Fabian Nietlispach, et al.
Journal of Cardiac Failure|February 25, 2017
N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHFNasser Davarzani, Sandra Sanders-van Wijk, Joël Karel, et al.
JACC. Heart Failure|March 14, 2014
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)Sandra Sanders-van Wijk, Antoinette D I van Asselt, Hans Rickli, et al.
European Heart Journal|November 10, 2011
End-of-life preferences of elderly patients with chronic heart failureHans-Peter Brunner-La Rocca, Peter Rickenbacher, Stefano Muzzarelli, et al.
The American Journal of Medicine|May 4, 2019
Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF TrialJustas Simonavičius, Sandra Sanders van-Wijk, Peter Rickenbacher, et al.
JACC. Cardiovascular Interventions|August 20, 2021
Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 TrialJochen Wöhrle, Bruno Scheller, Julia Seeger, et al.
Circulation. Cardiovascular Interventions|January 10, 2022
Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2Norman Mangner, Ahmed Farah, Marc-Alexander Ohlow, et al.
Pageof 4